334 related articles for article (PubMed ID: 30940653)
1. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy.
Gregory MA; Nemkov T; Park HJ; Zaberezhnyy V; Gehrke S; Adane B; Jordan CT; Hansen KC; D'Alessandro A; DeGregori J
Clin Cancer Res; 2019 Jul; 25(13):4079-4090. PubMed ID: 30940653
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
[TBL] [Abstract][Full Text] [Related]
3. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
7. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.
Jin H; Wang S; Zaal EA; Wang C; Wu H; Bosma A; Jochems F; Isima N; Jin G; Lieftink C; Beijersbergen R; Berkers CR; Qin W; Bernards R
Elife; 2020 Oct; 9():. PubMed ID: 33016874
[TBL] [Abstract][Full Text] [Related]
8. Peperomin E and its orally bioavailable analog induce oxidative stress-mediated apoptosis of acute myeloid leukemia progenitor cells by targeting thioredoxin reductase.
Wang X; Gao M; Zhang J; Ma Y; Qu W; Liang J; Wu H; Wen H
Redox Biol; 2019 Jun; 24():101153. PubMed ID: 30909158
[TBL] [Abstract][Full Text] [Related]
9. Importance of glutamine metabolism in leukemia cells by energy production through TCA cycle and by redox homeostasis.
Goto M; Miwa H; Shikami M; Tsunekawa-Imai N; Suganuma K; Mizuno S; Takahashi M; Mizutani M; Hanamura I; Nitta M
Cancer Invest; 2014 Jul; 32(6):241-7. PubMed ID: 24762082
[TBL] [Abstract][Full Text] [Related]
10. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
[TBL] [Abstract][Full Text] [Related]
11. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.
Di Marcantonio D; Martinez E; Sidoli S; Vadaketh J; Nieborowska-Skorska M; Gupta A; Meadows JM; Ferraro F; Masselli E; Challen GA; Milsom MD; Scholl C; Fröhling S; Balachandran S; Skorski T; Garcia BA; Mirandola P; Gobbi G; Garzon R; Vitale M; Sykes SM
Clin Cancer Res; 2018 Feb; 24(3):608-618. PubMed ID: 29127121
[No Abstract] [Full Text] [Related]
13. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Willems L; Jacque N; Jacquel A; Neveux N; Maciel TT; Lambert M; Schmitt A; Poulain L; Green AS; Uzunov M; Kosmider O; Radford-Weiss I; Moura IC; Auberger P; Ifrah N; Bardet V; Chapuis N; Lacombe C; Mayeux P; Tamburini J; Bouscary D
Blood; 2013 Nov; 122(20):3521-32. PubMed ID: 24014241
[TBL] [Abstract][Full Text] [Related]
15. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
16. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia.
Gao HE; Sun Y; Ding YH; Long J; Liu XL; Yang M; Ji Q; Li YH; Chen Y; Zhang Q; Gao YD
Oncotarget; 2017 Jun; 8(24):38990-39000. PubMed ID: 28473664
[TBL] [Abstract][Full Text] [Related]
18. Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.
Zacharias NM; Baran N; Shanmugavelandy SS; Lee J; Lujan JV; Dutta P; Millward SW; Cai T; Wood CG; Piwnica-Worms D; Konopleva M; Bhattacharya PK
Mol Cancer Ther; 2019 Nov; 18(11):1937-1946. PubMed ID: 31387889
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
20. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
